Crosslinking of α-synuclein by advanced glycation endproducts — an early pathophysiological step in Lewy body formation?

α-Synuclein in filamentous inclusions of Lewy bodies from Parkinson’s disease and dementia with Lewy bodies

Spillantini, M. G., Crowther, R. A., Jakes, R., Hasegawa, M., & Goedert, M. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.11.6469 · Cited by 3,151 · see citing works

Enhanced cellular oxidant stress by the interaction of advanced glycation end products with their receptors/binding proteins

Yan, S. D., Schmidt, A. M., Anderson, G. M., Zhang, J., Brett, J., Zou, Y., Pinsky, D. J., & Stern, D. (1994) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)36966-1 · Cited by 1,305 · see citing works

Tumor necrosis factor-α (TNF-α) increases both in the brain and in the cerebrospinal fluid from parkinsonian patients

Mogi, M., Harada, M., Riederer, P., Narabayashi, H., Fujita, K., & Nagatsu, T. (1994) · Neuroscience Letters · doi:10.1016/0304-3940(94)90746-3 · Cited by 986 · see citing works

Interleukin-1β, interleukin-6, epidermal growth factor and transforming growth factor-α are elevated in the brain from parkinsonian patients

Mogi, M., Harada, M., Kondo, T., Riederer, P., Inagaki, H., Minami, M., & Nagatsu, T. (1994) · Neuroscience Letters · doi:10.1016/0304-3940(94)90508-8 · Cited by 855 · see citing works

Free radical generation by early glycation products: A mechanism for accelerated atherogenesis in diabetes

Mullarkey, C. J., Edelstein, D., & Brownlee, M. (1990) · Biochemical and Biophysical Research Communications · doi:10.1016/s0006-291x(05)80875-7 · Cited by 691 · see citing works

Understanding cell death in parkinson's disease

Jenner, P., & Olanow, C. W. (1998) · Annals of Neurology · doi:10.1002/ana.410440712 · Cited by 686 · see citing works

Alterations in the distribution of glutathione in the substantia nigra in Parkinson's disease

Pearce, R. K. B., Owen, A., Daniel, S. E., Jenner, P. G., & MARSDEN, C. D. (1997) · Journal of Neural Transmission · doi:10.1007/bf01291884 · Cited by 350 · see citing works

Glycoxidation and oxidative stress in Parkinson disease and diffuse Lewy body disease

Castellani, R. J., Smith, M. A., Richey, G. L., & Perry, G. L. (1996) · Brain Research · doi:10.1016/0006-8993(96)00729-9 · Cited by 315 · see citing works

Glutathione-dependent detoxification of α-oxoaldehydes by the glyoxalase system: involvement in disease mechanisms and antiproliferative activity of glyoxalase I inhibitors

Thornalley, P. J. (1998) · Chemico-Biological Interactions · doi:10.1016/s0009-2797(97)00157-9 · Cited by 308 · see citing works

Alzheimer's disease – synergistic effects of glucose deficit, oxidative stress and advanced glycation endproducts

Münch, G. W., Schinzel, R., Loske, C., Wong, A. O., Durany, N., Li, J. J., Vlassara, H., Smith, M. A., Perry, G. L., & Riederer, P. F. (1998) · Journal of Neural Transmission · doi:10.1007/s007020050069 · Cited by 302 · see citing works

Advanced glycation endproducts in ageing and Alzheimer's disease

Münch, G. W., Thome, J., Foley, P. B., Schinzel, R., & Riederer, P. F. (1997) · Brain Research Reviews · doi:10.1016/s0165-0173(96)00016-1 · Cited by 275 · see citing works

Amadorins: Novel Post-Amadori Inhibitors of Advanced Glycation Reactions

Khalifah, R. G., Baynes, J., & Hudson, B. G. (1999) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1999.0371 · Cited by 268 · see citing works

Sequestration of iron by Lewy bodies in Parkinson's disease

Castellani, R. J., Siedlak, S. L., Perry, G., & Smith, M. A. (2000) · Acta Neuropathologica · doi:10.1007/s004010050001 · Cited by 265 · see citing works

Nigral and extranigral pathology in Parkinson's disease.

Braak, H., Braak, E., Yilmazer‐Hanke, D., Schultz, C., de Vos, R. A. I., & Jansen, E. N. H. (1995) · PubMed · Cited by 198 · see citing works

High molecular weight hyaluronic acid inhibits advanced glycation endproduct‐induced NF‐κB activation and cytokine expression

Neumann, A., Schinzel, R., Palm, D., Riederer, P. F., & Münch, G. W. (1999) · FEBS Letters · doi:10.1016/s0014-5793(99)00731-0 · Cited by 195 · see citing works

α-Synuclein immunoreactivity in dementia with Lewy bodies: morphological staging and comparison with ubiquitin immunostaining

Gómez‐Tortosa, E., Newell, K. L., Irizarry, M. C., Sanders, J. L., & Hyman, B. T. (2000) · Acta Neuropathologica · doi:10.1007/s004010051135 · Cited by 162 · see citing works

Understanding Parkinson's Disease

Youdim, M. B. H., & Riederer, P. F. (1997) · Scientific American · doi:10.1038/scientificamerican0197-52 · Cited by 144 · see citing works

Transition Metals Bind to Glycated Proteins Forming Redox Active “Glycochelates”: Implications for the Pathogenesis of Certain Diabetic Complications

Qian, M., Liu, M., & Eaton, J. W. (1998) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1998.9326 · Cited by 126 · see citing works

Transition metal‐mediated glycoxidation accelerates cross‐linking of β‐amyloid peptide

Loske, C., Gerdemann, A., Schepl, W., Wycislo, M., Schinzel, R., Palm, D., Riederer, P. F., & Münch, G. W. (2000) · European Journal of Biochemistry · doi:10.1046/j.1432-1327.2000.01452.x · Cited by 108 · see citing works

Parkinson's disease: a major hypokinetic basal ganglia disorder

Sian, J., Gerlach, M., Youdim, M. B. H., & Riederer, P. F. (1999) · Journal of Neural Transmission · doi:10.1007/s007020050171 · Cited by 89 · see citing works

Advanced glycation end products in neurodegeneration: More than early markers of oxidative stress?

Münch, G. W., Gerlach, M., Sian, J., Wong, A. O., & Riederer, P. F. (1998) · Annals of Neurology · doi:10.1002/ana.410440713 · Cited by 73 · see citing works

Involvement of α-synuclein in Parkinson's disease and other neurodegenerative disorders

Krüger, R., Müller, T., & Riess, O. H. (2000) · Journal of Neural Transmission · doi:10.1007/s007020050002 · Cited by 70 · see citing works

The cognition-enhancing drug tenilsetam is an inhibitor of protein crosslinking by advanced glycosylation

Münch, G. W., Taneli, Y., Schraven, E., Schindler, U., Schinzel, R., Palm, D., & Riederer, P. F. (1994) · Journal of Neural Transmission - Parkinsons Disease and Dementia Section · doi:10.1007/bf02260940 · Cited by 69 · see citing works

Advanced glycation endproducts are associated with Hirano bodies in Alzheimer's disease

Münch, G. W., Cunningham, A. M., Riederer, P. F., & Braak, E. (1998) · Brain Research · doi:10.1016/s0006-8993(98)00328-x · Cited by 57 · see citing works

Early contribution of oxidative glycation in Alzheimer disease

Smith, M. A., Tabaton, M., & Perry, G. L. (1996) · Neuroscience Letters · doi:10.1016/0304-3940(96)13100-1 · Cited by 32 · see citing works

Distribution of advanced glycation end products in the cerebellar neurons of dogs

Weber, K., Schmahl, W. W., & Münch, G. W. (1998) · Brain Research · doi:10.1016/s0006-8993(97)01421-2 · Cited by 15 · see citing works

Mitochondrial Dysfunction and Oxidative Damage in parkin-deficient Mice

Palacino, J. J., Sagi, D., Goldberg, M. S., Krauss, S., Motz, C., Wacker, M., Klose, J., & Shen, J. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m401135200 · Cited by 995 · see citing works

The Role of Advanced Glycation End Products in Aging and Metabolic Diseases: Bridging Association and Causality

Chaudhuri, J., Bains, Y., Guha, S., Kahn, A., Hall, D., Bose, N., Gugliucci, A., & Kapahi, P. (2018) · Cell Metabolism · doi:10.1016/j.cmet.2018.08.014 · Cited by 669 · see citing works

Advanced glycation end products (AGEs) and other adducts in aging-related diseases and alcohol-mediated tissue injury

Rungratanawanich, W., Qu, Y., Wang, X., Essa, M. M., & Song, B.-J. (2021) · Experimental & Molecular Medicine · doi:10.1038/s12276-021-00561-7 · Cited by 411 · see citing works

Iron Toxicity in Diseases of Aging: Alzheimer's Disease, Parkinson's Disease and Atherosclerosis

Altamura, S., & Muckenthaler, M. U. (2009) · Journal of Alzheimer's Disease · doi:10.3233/jad-2009-1010 · Cited by 369 · see citing works

Brain iron pathways and their relevance to Parkinson's disease

Berg, D., Gerlach, M., Youdim, M. B. H., Double, K. L., Zecca, L., Riederer, P., & Becker, G. (2001) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2001.00608.x · Cited by 362 · see citing works

Evidence of Oxidative Stress in the Neocortex in Incidental Lewy Body Disease

Dalfó, E., Portero-Otín, M., Ayala, V., Martínez, A., Pamplona, R., & Ferrer, I. (2005) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/01.jnen.0000179050.54522.5a · Cited by 261 · see citing works

In vivo detection of iron and Neuromelanin by transcranial sonography: a new approach for early detection of substantia nigra damage

Zecca, L., Berg, D., Arzberger, T., Ruprecht, P., Rausch, W. D., Musicco, M., Tampellini, D., Riederer, P., Gerlach, M., & Becker, G. (2005) · Movement Disorders · doi:10.1002/mds.20550 · Cited by 214 · see citing works

General aspects of neurodegeneration

Jellinger, K. A. (2003) · Journal of Neural Transmission. Supplementa · doi:10.1007/978-3-7091-0643-3_7 · Cited by 126 · see citing works

Advanced glycation end products and protein carbonyl levels in plasma reveal sex-specific differences in Parkinson's and Alzheimer's disease

Sharma, A., Weber, D., Raupbach, J., Dakal, T. C., Fließbach, K., Ramirez, A., Grune, T., & Wüllner, U. (2020) · Redox Biology · doi:10.1016/j.redox.2020.101546 · Cited by 120 · see citing works

Recent Advances in α-Synuclein Functions, Advanced Glycation, and Toxicity: Implications for Parkinson’s Disease

Guerrero, E., Vasudevaraju, P., Hegde, M. L., Britton, G. B., & Rao, K. S. (2013) · Molecular Neurobiology · doi:10.1007/s12035-012-8328-z · Cited by 121 · see citing works

Ceruloplasmin gene variations and substantia nigra hyperechogenicity in Parkinson disease

Hochstrasser, H., Bauer, P., Walter, U., Behnke, S., Spiegel, J., Csoti, I., Zeiler, B., Bornemann, A., Pahnke, J., Becker, G., et al. (2004) · Neurology · doi:10.1212/01.wnl.0000144276.29988.c3 · Cited by 111 · see citing works

Age- and stage-dependent glyoxalase I expression and its activity in normal and Alzheimer's disease brains

Kuhla, B., Boeck, K., Schmidt, A., Ogunlade, V., Arendt, T., Münch, G., & Lüth, H.-J. (2007) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2005.11.007 · Cited by 108 · see citing works

Glycation affects fibril formation of Aβ peptides

Emendato, A., Milordini, G., Zacco, E., Sicorello, A., Dal Piaz, F., Guerrini, R., Thorogate, R., Picone, D., & Pastore, A. (2018) · Journal of Biological Chemistry · doi:10.1074/jbc.ra118.002275 · Cited by 65 · see citing works

Delineation of Neuroprotective Effects and Possible Benefits of AntioxidantsTherapy for the Treatment of Alzheimer's Diseases by Targeting Mitochondrial-Derived Reactive Oxygen Species: Bench to Bedside

Walia, V., Kaushik, D., Mittal, V., Kumar, K., Verma, R., Parashar, J., Akter, R., Rahman, M. H., Bhatia, S., Al-Harrasi, A., et al. (2022) · Molecular Neurobiology · doi:10.1007/s12035-021-02617-1 · Cited by 47 · see citing works

Ironing out Parkinson's disease: is therapeutic treatment with iron chelators a real possibility?

Kaur, D., & Andersen, J. K. (2002) · Aging Cell · doi:10.1046/j.1474-9728.2002.00001.x · Cited by 44 · see citing works

Paraquat and iron exposure as possible synergistic environmental risk factors in Parkinson’s disease

Andersen, J. K. (2003) · Neurotoxicity Research · doi:10.1007/bf03033150 · Cited by 40 · see citing works

Prominent astrocytic alpha-synuclein pathology with unique post-translational modification signatures unveiled across Lewy body disorders

Altay, M. F., Liu, A. K. L., Holton, J. L., Parkkinen, L., & Lashuel, H. A. (2022) · Acta Neuropathologica Communications · doi:10.1186/s40478-022-01468-8 · Cited by 83 · see citing works

Novel antibodies to synuclein show abundant striatal pathology in Lewy body diseases

Duda, J. E., Giasson, B. I., Mabon, M. E., Lee, V. M. ‐., & Trojanowski, J. Q. (2002) · Annals of Neurology · doi:10.1002/ana.10279 · Cited by 329 · see citing works

Alpha-synuclein truncation and disease

Ritchie, C. M., & Thomas, P. (2012) · Health · doi:10.4236/health.2012.431175 · Cited by 9 · see citing works

13 C and 15 N Resonance Assignments of Alpha Synuclein Fibrils Amplified from Lewy Body Dementia TissuePreprint

Barclay, A. M., Dhavale, D. D., Borcik, C. G., et al. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.01.09.523339

13C and 15N Resonance Assignments of Alpha Synuclein Fibrils Amplified from Lewy Body Dementia TissuePreprint

Barclay, A. M., Dhavale, D. D., Borcik, C. G., et al. (2023) · Research Square · doi:10.21203/rs.3.rs-2460685/v1